Pasithea Therapeutics (KTTA) Expected to Announce Earnings on Monday

Pasithea Therapeutics (NASDAQ:KTTA) will likely be announcing its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Pasithea Therapeutics Stock Up 1.9%

Shares of KTTA stock opened at $0.80 on Friday. The stock’s 50-day moving average price is $0.82 and its 200 day moving average price is $0.85. The stock has a market capitalization of $18.40 million, a PE ratio of -0.16 and a beta of 0.20. Pasithea Therapeutics has a 52-week low of $0.28 and a 52-week high of $3.79.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KTTA. Two Sigma Investments LP purchased a new stake in shares of Pasithea Therapeutics during the 3rd quarter worth $26,000. Citadel Advisors LLC lifted its stake in shares of Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock valued at $48,000 after purchasing an additional 20,483 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pasithea Therapeutics by 113.9% in the fourth quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock valued at $70,000 after purchasing an additional 29,020 shares during the period. Jane Street Group LLC boosted its holdings in Pasithea Therapeutics by 137.0% during the fourth quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after buying an additional 34,319 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in Pasithea Therapeutics during the fourth quarter worth about $375,000. Hedge funds and other institutional investors own 23.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KTTA. HC Wainwright initiated coverage on Pasithea Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $3.00 target price on the stock. Wall Street Zen raised Pasithea Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, January 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, December 29th. Finally, Zacks Research upgraded shares of Pasithea Therapeutics to a “hold” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.